Nanjing BioPoint Diagnostic Technology Co. Ltd (Nanjing BioPoint) has its main R&D centre located in the Jiangsu Life science &. Technology Innovation Park (http://www.jiangsulifepark.com/), about 18 km from the city of Nanjing, capital of Jiangsu province, China.
The building inside the Jiangsu Life Science &. Technology Innovation Park where Nanjing BioPoint R&D centre is located.
There are 12 universities and colleges in the neighbourhood of the park, which are among the 53 colleges and universities, 224 engineering and technology research centres and 55 key research laboratories located in Nanjing. In particular, Nanjing University, China Pharmaceutical University, Nanjing Normal University and Nanjing University of Traditional Chinese Medicine are among the top ranking universities in China, with vast human capital and the state of arts research facilities.
Nanjing BioPoint is aimed to develop point of care diagnostic product targeted for infectious disease of worldwide significance, for instance liver disease, tuberculosis, malaria and AIDS. A very significant number of the sufferers of these diseases are living in countries and areas with poor or no hospital access, which leaves the point of care diagnostic products in many instances the only viable solution for discovering and monitoring the development of the diseases.
Countries where the Burnet Institute has field offices.
Burnet Institute in Melbourne, Australia has many years’ experiences working in the field of developing countries. It not only developed expertise in epidemiology of the diseases, which provided the insight in developing diagnostic products that targets significant biomarker for controlling the diseases, but also gained invaluable knowledge about the mode of deliveries which ensures the products that the Nanjing BioPoint developed will be well suited and perform well in the often very challenging environment where they will be used.